Literature DB >> 3396162

C5a decreases regional coronary blood flow and myocardial function in pigs: implications for a granulocyte mechanism.

S E Martin1, D E Chenoweth, R L Engler, D M Roth, J C Longhurst.   

Abstract

Granulocytes cause some of the pathophysiological effects associated with the capillary no-reflow phenomenon during ischemia and in ischemia-reperfusion injury. However, no study has examined the consequences of in vivo granulocyte activation during normal perfusion pressures. In this study, we examined the effects of intracoronary administration of the complement component C5a, which is known to be a potent granulocyte activating factor. Nine open-chest, anesthetized pigs were instrumented to monitor regional coronary blood flow and segment shortening, left ventricular dP/dt, heart rate, and pulmonary artery and aortic blood pressures and to sample arterial and regional coronary venous blood for oxygen content and complete blood counts. Intracoronary infusion of human or porcine C5a in doses ranging from 10 to 500 ng produced a significant reduction in regional coronary blood flow and myocardial function. Although perfusion pressure and heart rate remained constant, venous oxygen content fell, indicating an imbalance between myocardial oxygen supply and demand. In addition, the arteriovenous difference of white blood cells was increased significantly after anaphylatoxin infusion, indicating intravascular trapping in the myocardium. Granulocytes accounted entirely for the differences in leukocyte counts because no significant changes in platelet, lymphocyte, or hematocrit levels were observed. Injection of vehicle alone did not alter any of the monitored variables.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3396162     DOI: 10.1161/01.res.63.2.483

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  7 in total

Review 1.  St Cyres lecture. Endothelium in control.

Authors:  A H Henderson
Journal:  Br Heart J       Date:  1991-03

2.  Plasma-derived Extracellular Vesicles Contain Predictive Biomarkers and Potential Therapeutic Targets for Myocardial Ischemic (MI) Injury.

Authors:  Esther Sok Hwee Cheow; Woo Chin Cheng; Chuen Neng Lee; Dominique de Kleijn; Vitaly Sorokin; Siu Kwan Sze
Journal:  Mol Cell Proteomics       Date:  2016-05-27       Impact factor: 5.911

3.  Treatment with the C5a receptor antagonist ADC-1004 reduces myocardial infarction in a porcine ischemia-reperfusion model.

Authors:  Jesper van der Pals; Sasha Koul; Patrik Andersson; Matthias Götberg; Joey F A Ubachs; Mikael Kanski; Håkan Arheden; Göran K Olivecrona; Bengt Larsson; David Erlinge
Journal:  BMC Cardiovasc Disord       Date:  2010-09-27       Impact factor: 2.298

Review 4.  Proclivity of activated neutrophils to cause postischemic cardiac dysfunction: participation in stunning?

Authors:  K Mullane; R Engler
Journal:  Cardiovasc Drugs Ther       Date:  1991-10       Impact factor: 3.727

5.  The anaphylatoxins C3a and C5a are vasodilators in the canine coronary vasculature in vitro and in vivo.

Authors:  W A Schumacher; J C Fantone; S E Kunkel; R C Webb; B R Lucchesi
Journal:  Agents Actions       Date:  1991-11

Review 6.  Complement activation and cardiac surgery: a novel target for improving outcomes.

Authors:  Gregory L Stahl; Stanton K Shernan; Peter K Smith; Jerrold H Levy
Journal:  Anesth Analg       Date:  2012-07-13       Impact factor: 5.108

Review 7.  Function, structure and therapeutic potential of complement C5a receptors.

Authors:  P N Monk; A-M Scola; P Madala; D P Fairlie
Journal:  Br J Pharmacol       Date:  2007-07-02       Impact factor: 8.739

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.